Academic literature on the topic 'Obese PCOS'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Obese PCOS.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Obese PCOS"
1
Al-Jumaili, Farah T. O., Aqeel Jafar Naji, and Thamer Mutlag Jasim. "Evaluation of Some Biochemical Markers in Patient's with Polycystic Ovarian Syndrome." Journal of Biotechnology Research Center 9, no. 2 (2015): 37–45. http://dx.doi.org/10.24126/jobrc.2015.9.2.433.
Full textAbstract:
The present study aims to detect several biochemical markers associated with PCOS (Polycysticovary syndrome) in Iraqi women comparing the results with control normal fertile women andalso studying the effect of obesity on the same biochemical markers. Ninety eight women withPCOS, 51 non-obese [body mass index (BMI) less than 25 kg/m2] and 47 obese (BMI >25 kg/m2)were enrolled for the study. Each group of them was compared forty normal fertile women ascontrol group matched for each in age and BMI. The first part of this study was devoted to themeasurement of Body Mass Index (BMI) and Waist Hip Ratio (WHR), subdivided PCOSaccording to the body mass index, and measurement of fasting insulin, fasting glucose,Homeostatic Model Assessment (HOMA), HbA1c and lipid profile. A significant differences wasfound in HbA1c (P≤0.0001) VLDL (p≤0.0001), triglyceride (p≤0.05) and cholesterol (p≤0.05)between obeses and lean PCOS patients. Insulin serum level (P≤0.0001) was highly significantlyincreased in obeses PCOS patients as compared to obeses control, the serum insulin (P≤0.0001)also significantly increased in lean PCOS women when compared with lean control. There was asignificant differences between HOMA (P≤0.05) in obeses PCOS patients than in the obesecontrol group and between obese and lean women PCOS patients.
2
Raeisi, Tahereh, Hossein Rezaie, Mina Darand, et al. "Circulating resistin and follistatin levels in obese and non-obese women with polycystic ovary syndrome: A systematic review and meta-analysis." PLOS ONE 16, no. 3 (2021): e0246200. http://dx.doi.org/10.1371/journal.pone.0246200.
Full textAbstract:
This meta-analysis was performed to resolve the inconsistencies regarding resistin and follistatin levels in women with polycystic ovary syndrome (PCOS) by pooling the available evidence. A systematic literature search using PubMed and Scopus was carried out through November 2020 to obtain all pertinent studies. Weighted mean differences (WMDs) with corresponding 95% confidence intervals (CIs) were calculated to evaluate the strength of the association between the levels of resistin and follistatin with PCOS in the overall and stratified analysis by obesity status. A total of 47 publications, 38 for resistin (2424 cases; 1906 controls) and 9 studies for follistatin (815 cases; 328 controls), were included in the meta-analysis. Resistin levels were significantly higher in PCOS women compared with non-PCOS controls (WMD = 1.96 ng/ml; 95%CI = 1.25–2.67, P≤0.001) as well as in obese PCOS women vs. obese controls, and in non-obese PCOS women compared with non-obese controls, but not in obese PCOS vs. non-obese PCOS patients,. A significantly increased circulating follistatin was found in PCOS patients compared with the controls (WMD = 0.44 ng/ml; 95%CI = 0.30–0.58, P≤0.001) and in non-obese PCOS women compared with non-obese controls and in obese PCOS women vs. obese controls, but, no significant difference in follistatin level was observed in obese PCOS compared with non-obese PCOS women. Significant heterogeneity and publication bias was evident for some analyses. Circulating levels of resistin and follistatin, independent of obesity status, are higher in women with PCOS compared with controls, showing that these adipokines may contribute to the pathology of PCOS.
3
Reda, Ahmed M., AhmedI Abul Soud, Ahmed H. El Sawaf, Omnia I. Ezzat, Tarek M. Salman, and Hussein AL Sawaf. "Association of altered serum levels of Chemerin, Paraoxonase-1 (PON1), Asymmetric Dimethyl arginine (ADMA) and obesitin the development of Polycystic Ovarian Syndrome (PCOS) in Egyptian women." Indian Journal of Pharmaceutical and Biological Research 3, no. 03 (2015): 35–43. http://dx.doi.org/10.30750/ijpbr.3.3.6.
Full textAbstract:
Chemerinwas recently added to the adipokine family and was identified in human ovarian follicles and follicular fluid that suggests a direct correlation between chemerin and PCOS. Asymmetric dimethyl arginine (ADMA) is involved in endothelial dysfunctionthe atherogenic potential of ADMA has been investigated in young patients with PCOS. Oxidative stress is considered to be implicated in the pathophysiology of PCOS.Paraoxonase 1 (PON1) is an antioxidant enzyme and its concentration has been shown to be inversely associated with oxidative stress. Objectives: Evaluation of serum chemerin, ADMA, PON1in obese and non-obese polycystic ovarian patients to postulate their role in pathogenesis of PCOS. Methods: Ninetynuligravida women aged 20-35 (60 with PCOS and 30 controls) were recruited. Fasting blood was obtained on day 2 or 3 of the menstrual cycle. Clinical evaluation, hormonal profile, Chemerin, ADMA and PON1 were assessed. Results: There was a significant increase in serum chemerinlevels in PCOS obese group when compared with PCOS non obese patients and healthy controls non obese and obese respectively. Serum ADMA level was increased significantly in PCOS obese group as compared to the PCOS non obese group , control non obese and control obese. Paraoxonase was decreased stepwise significantly from the control non obese group and control obese group to PCOS non obese patients then PCOS obese patients to. Conclusions: it could be suggested that increased chemerin has a role in PCOS development andaltered ADMA and PON1 associated withobesity and oxidative stress may exacerbate the condition.
4
Banu, IM, MA Wahab, BC Debnath, D. Begum, and MI Arslan. "Characteristics of Insulin and Androgen Status in Polycystic Ovary Syndrome." Bangladesh Journal of Medical Biochemistry 3, no. 1 (2013): 11–15. http://dx.doi.org/10.3329/bjmb.v3i1.13801.
Full textAbstract:
Polycystic Ovary Syndrome (PCOS) was originally described as a syndrome of amenorrhea, hirsutism and obesity associated with enlarged polycystic ovaries. There is increased androgen level and in some, insulin resistance (IR). Etiological relationship of androgen excess and IR in PCOS is not established. Influence of obesity on PCOS is controversial. This study was designed to see the androgen and insulin status in PCOS among obese and non-obese patients. It was a case-control study. Of total 80 study subjects, 60 primary infertile women suffering from PCOS were cases (30 obese and 30 non-obese). Age and BMI matched 20 healthy women having normal menstrual cycles were controls (10 obese and 10 non-obese). Age range of all were 20-40 years. Fasting plasma glucose, fasting S. Insulin and free Testosterone were measured. Insulin resistance (IR) was assessed by fasting glucose to insulin ratio (<4.5). Subjects with DM or known endocrine disorders that may be associated with abnormal S.Insulin or plasma glucose concentration were excluded. No significant difference of fasting plasma glucose between PCOS (obese or non-obese) and respective controls (P>0.5, in each) were observed. Significant difference of fasting S. Insulin and testosterone were observed between PCOS (both obese and non-obese) and respective controls (P<0.01 in each), but there was no significant difference between obese and non-obese PCOS (P>0.05). There was no significant difference of S.Testosterone between obese and non-obese PCOS(P>0.05). There was also no significant difference of IR between obese and non-obese PCOS, but the ratio was <4.5 (indicating IR in both). There were no significant correlation of S.Insulin with Testosterone in any group of PCOS (obese and non-obese) (P>0.05). Increased S.Insulin and Testosterone was seen in PCOS irrespective of BMI. Further studies with larger sample size is recommended to assess etiological relationship between insulin and testosterone in PCOS. DOI: http://dx.doi.org/10.3329/bjmb.v3i1.13801 Bangladesh J Med Biochem 2010; 3(1): 11-15
5
Shehzad, Maheen, Naila Abdul Sattar, and Nadia Ishaq. "Insulin Resistance in young obese females with and without Polycystic Ovary Syndrome." International Journal of Endorsing Health Science Research (IJEHSR) 10, no. 1 (2022): 31–35. http://dx.doi.org/10.29052/ijehsr.v10.i1.2022.31-35.
Full textAbstract:
Background: The present study intends to determine the comparative insulin resistance (IR) among young obese females with and without polycystic ovary syndrome (PCOs) using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).
 Methodology: During this comparative cross-sectional study, a total of 300 young obese females were evaluated for the presence of PCOS and insulin resistance. Based on the PCOs diagnosis, 250 obese PCOs females were included in group 1, and group 2 comprised 50 obese non-PCOs females. With the demographic details, patients' diabetic and lipid profiles were also evaluated, and the difference in the inference between the groups was drawn using SPSS version 22.0.
 Results: It is to note that more than 90% of the young obese PCOs females were diagnosed with type 2 diabetes mellitus (T2DM) while none of the obese non-PCOs females had diabetes. Furthermore, the HOMA-IR score was significantly high among young obese females diagnosed with PCOs (16.30 ± 1.62) as compared to those without PCOs (3.47 ± 0.37) (p<0.01).
 Conclusion: It is concluded from the study results that young obese females with PCOS are more prone to develop insulin resistance than those without PCOs.
6
Guzelkas, Ismail, Zerrin Orbak, Hakan Doneray, Nurinnisa Ozturk, and Nevin Sagsoz. "Serum kisspeptin, leptin, neuropeptide Y, and neurokinin B levels in adolescents with polycystic ovary syndrome." Journal of Pediatric Endocrinology and Metabolism 35, no. 4 (2022): 481–87. http://dx.doi.org/10.1515/jpem-2021-0487.
Full textAbstract:
Abstract Objectives Polycystic ovary syndrome (PCOS) is characterized by ovarian dysfunction, clinical and/or biochemical hyperandrogenism, and polycystic ovaries. Its pathogenesis is still unclear. This study aimed to investigate the relationship between kisspeptin, leptin, neuropeptide Y (NPY), and neurokinin B (NKB) levels for evaluating the pathogenesis of PCOS. Methods Levels of these parameters were analyzed in 20 patients with PCOS, and 16 healthy adolescents. Results Serum NPY levels were significantly higher in the obese and non-obese PCOS group (p<0.01). There was a negative correlation between the kisspeptin and the NKB levels (p<0.01) in the PCOS group but not in the control group. This negative correlation was also found in both PCOS groups (p<0.01). In the obese PCOS group, serum kisspeptin levels were significantly lower than the control and non-obese PCOS groups (p<0.05) although serum leptin and NPY levels were significantly higher in the obese PCOS group (p<0.01). Conclusions The high NPY levels in both obese and non-obese patients with PCOS indicate that NPY plays a role in the pathogenesis independently from obesity. Significantly high leptin and low kisspeptin levels in the obese PCOS group suggested that they may be associated with obesity rather than PCOS.
7
Waheed,, Huda J., Perry H. Saifallah, and Isam N. Salman. "Study of Some Cytokines and Hormones in a Sample of Iraqi women with Polycystic ovarian syndrome and Their Relation to Obesity." Al Mustansiriyah Journal of Pharmaceutical Sciences 13, no. 2 (2013): 58–64. http://dx.doi.org/10.32947/ajps.v13i2.201.
Full textAbstract:
The present study aimed to measure serum vaspin and apelin levels in women with PCOS to show their rule in the pathogenesis of PCOS. Ninety eight women with PCOS, 51 non-obese [body mass index (BMI) less than 25 kg/m2] and 47 obese (BMI >25 kg/m2) were enrolled in the study. Each group is compared to apparently healthy women as a control group matched for age and BMI. Clinical history, anthropometric measurements and biochemical and hormonal analysis were determined. The mean serum level of vaspin and apelin showed statistically significant difference between PCOS patients (non-obese and obese) compared to control women (non-obese and obese) respectively. Also, the levels of both parameters (vaspin, apelin)showed significant differences between PCOS obese patients and non-obese ones. It is concluded that serum vaspin and apelin level increased in PCOS women particularly the obese. These data suggest their involvement in the pathogenesis of PCOS
8
Zainab, Saadia, Tayyaba Batool, Samia Sarwar, Iram Qamar, Noor-Ul Ain, and Qurat-Ul Ain. "Oxidative Marker and Insulin Resistance in Women with PCOS." Pakistan Journal of Medical and Health Sciences 16, no. 2 (2022): 707–9. http://dx.doi.org/10.53350/pjmhs22162707.
Full textAbstract:
Introduction: Polycystic Ovary Disorder may be a multifactorial reproductive issue and a leading cause of female infertility around the world. Confirmations have appeared that Oxidative Stress and diminished antioxidant status are often connected with PCOS. Oxidative stretch (OS) which plays a key part within the pathogenesis of CVD has also been documented in obese women with PCOS. Oxidative stress may have a part within the pathophysiology of PCOS and impact female reproductive system leading to infertility but the exact cause of OS in PCOS isn't totally understood. Objective: To determine the levels of Glucose, Malondialdehyde, serum insulin and insulin resistance in non-obese and obese PCOS women. Material and Methods Study design: Case Control Settings: Lady Atchison Hospital Lahore Duration: Six months i.e. 1st January 2021 to 30th June 2021 Data Collection procedure: Case control study was conducted to analyzed 100 PCOS patients and 100 controls. Fasting plasma glucose was measured. Insulin resistance was calculated by HOMA-IR. Malonaldehyde is determined as Thiobarbituric corrosive reactive substances Insulin was assessed by chemiluminescent microparticle immunoassay. Results: The levels were higher of serum glucose in both obese and non-obese PCOS patients. Serum levels of insulin in obese PCOS patients were high as compared to non-obese PCOS patient. The level of CRP is in the higher side in PCOS patients whether obese or non-obese when it compared to control ones. The level of MDA also on the higher side in PCOS patients whether obese or non-obese when it compared to control ones Conclusion: Within the present study, we found expanded oxidative stress and low review inflammation shown by raised levels of MDA and CRP in ladies with polycystic ovary syndrome irrespective of obesity. They can be utilized as markers for women PCOS. In any case, the serum insulin levels and IR in non-obese patients with PCOS in spite of the fact that expanded in connection to BMI balanced controls, the values were inside the reference range. Keywords: Glucose, Insulin Resistance, Oxidative stress, PCOS, Insulin
9
Bayramoğlu, Elvan, Semra Çetinkaya, Servan Özalkak, et al. "Evaluation of the pathophysiological role of Fetuin A levels in adolescents with polycystic ovary syndrome." Journal of Pediatric Endocrinology and Metabolism 34, no. 7 (2021): 911–16. http://dx.doi.org/10.1515/jpem-2020-0524.
Full textAbstract:
Abstract Objectives Polycystic ovary syndrome (PCOS) is an endocrinopathy, in which hyperandrogenism and hyperinsulinism have both occurred. Fetuin-A, a natural inhibitor of tyrosine kinase, leads to insulin resistance. The aim was to evaluate the relationship between fetuin-A and hyperandrogenism and hyperinsulinism and the role of fetuin-A in the pathophysiology of PCOS. Methods Thirty-eight cases with PCOS and 40 healthy adolescents were included in the study. PCOS and controls were divided into obese/non-obese subgroups. LH, FSH, total and free testosterone (TT, FT), SHBG, androstenedione, DHEAS were measured in patients with PCOS. Fasting glucose, insulin, lipid profile, AST, ALT, HsCRP, and fetuin levels of PCOS patients and healthy controls were also measured. Results Fetuin-A levels were higher in PCOS patients than in controls. In the obese-PCOS group, when compared to non-obese PCOS patients; the levels of SHBG and HDL were low while cholesterol, LDL, triglyceride, HOMA-IR, FT, FAI, and HSCRP levels were high, but Fetuin-A levels were similar. In the obese-PCOS group, fetuin-A levels were higher than in obese-controls. HOMA-IR and fetuin-A levels were higher in non-obese PCOS patients than in non-obese controls. In the PCOS group, fetuin-A was positively correlated with TT, FT, FAI and androstenedione and negatively correlated with SHBG. Regression analysis demonstrated that FT, SHBG, and androstenedione significantly predicted fetuin-A levels (R2=54%). In non-obese PCOS patients and controls, fetuin-A was positively correlated with insulin and HOMA-IR. Conclusions These results suggest a relationship between androgen levels and fetuin-A in PCOS cases, independent of insulin resistance, and may shed light on further studies.
10
Saha, Amrita, Shashi Shukla, Preeti, and Divya. "Correlation of thyroid-stimulating hormone level with obesity in patients of polycystic ovary syndrome." International Journal of Reproduction, Contraception, Obstetrics and Gynecology 13, no. 8 (2024): 2075–81. http://dx.doi.org/10.18203/2320-1770.ijrcog20242074.
Full textAbstract:
Background: Polycystic ovarian syndrome (PCOS), a heterogeneous endocrine disorder is most common in women of the reproductive age group. Thyroid disorders and PCOS are two of the most common endocrine disorders in women. Although the etiopathogenesis of hypothyroidism and PCOS is completely different, these two disorders have many common features. An increase in ovarian volume and cystic changes in ovaries have been reported in primary hypothyroidism. The aim of this study was to find the correlation of thyroid-stimulating hormone (TSH) level in obese and non-obese women, who were diagnosed to have PCOS. Methods: The data of 161 women who visited the institution for diagnosis and management of PCOS were included in the study. Demographic data like age, height and weight of the women at the time of diagnosis of PCOS were collected and subjected to analysis. Results: The results showed that 15% obese PCOS women had high TSH level and 7% non- obese PCOS had high TSH level. Conclusions: The result of the study suggests that higher level of TSH seen in obese PCOS women than non -obese PCOS women.
Dissertations / Theses on the topic "Obese PCOS"
1
Steinheim, Elena. "Effects of insulin sensitizing drug metformin on clinical features, endocrine and metabolic profiles in obese women with polycystic ovary syndrome." Doctoral thesis, Humboldt-Universität zu Berlin, Medizinische Fakultät - Universitätsklinikum Charité, 2007. http://dx.doi.org/10.18452/15631.
Full textAbstract:
Metformineinnahme scheint reproduktive und metabolische Funktionen bei Frauen mit PCOS zu verbessern. Die zwiespältige aktuelle Studienlage kann bisher keine konkrete Aussage liefern, ob Metformin eine erfolgreiche therapeutische Möglichkeit des Syndroms darstellt. Ziel der vorliegenden randomisierten, placebo-kontrollierten Studie war es, die Auswirkung des antihyperglykämischen Medikaments Metformin in Kombination mit Ernährungsberatung und Sport auf übergewichtige Frauen mit PCOS zu ermitteln. Besondere Aufmerksamkeit galt der Wirkung des Medikaments hinsichtlich Insulin und Glukose-Stoffwechsel, endokrinologischen und biochemischen Parametern, sowie dem Menstruationszyklus. 46 adipöse Frauen mit PCOS im Alter von 22 bis 39 Jahren und mit einem mittleren BMI von 38,1 nahmen an der Studie teil. Die verabreichte Dosis von Metformin betrug 1,5 g (3x500 mg) täglich über einen Zeitraum von 16 Wochen. Gemessen wurden Veränderungen von FSH, LH, Oestradiol, Testosteron, DHEA-S, SHBG, Cholesterol, Triglyzeriden, Insulin, Glukose, HbA1c, Leptin und IGF-I im Serum. Monatlich wurde eine Ernährungsberatung angeboten. Jede Teilnehmerin erhielt darüber hinaus individuelle dietätische Beratung. Signifikante Gewichtsreduktion (P<br>Use of metformin seems to improve reproductive and metabolic abnormalities in women with PCOS. However, the disparity of results in clinical studies cannot give us a conclusive answer if metformin is a new line therapy of the syndrome. The present randomised, placebo-controlled study was designed to compare the antihyperglycemic drug metformin vs. placebo combined with lifestyle modification in the treatment of polycystic ovary syndrome in obese women. Special attention was paid to the effects of this medication on insulin and glucose metabolism, endocrine and biochemical parameters, and menstrual function. Forty six obese women with PCOS, aged between 22-39 years and mean BMI 38.1 were randomized to receive either metformin (500 mg three times a day for 16 weeks) or placebo. The metformin and placebo groups were matched for age, endocrinological and metabolic parameters. Changes in FSH, LH, estradiol, testosterone, DHEA-S and SHBG, total cholesterol, triglycerides, insulin, glucose, HbA1c, leptin and IGF-I were assessed. Group therapy with aspects in nutrition and physical activity was conducted monthly. Each woman received individual counselling by a dietician. Significant (P
2
Weidemann, Annchen. "The role of fructose restriction in addition to dietary modifications for weight loss and lifestyle improvement, on fertility outcome and other markers of metabolic syndrome (MS), in obese women with polycystic ovarian syndrome (PCOS)." Thesis, Stellenbosch : Stellenbosch University, 2012. http://hdl.handle.net/10019.1/71878.
Full textAbstract:
Thesis (MNutr)--Stellenbosch University, 2012.<br>ENGLISH ABSTRACT: The role of fructose restriction in addition to dietary modifications for weight loss and lifestyle improvement, on fertility outcome and other markers of metabolic syndrome, in obese women with polycystic ovarian syndrome (PCOS)
Introduction: At the time at which the current study was undertaken no data, as yet, existed on whether restriction of fructose, while treating obese patients with PCOS for weight loss, improves the clinical symptoms and metabolic/anthropometric profile so as to promote fertility.
Objectives: To evaluate the baseline intake of fructose, as well as the effect of restricting fructose intake from fruit and soft beverages to less than 20 g daily, as well as to provide guidelines for weight loss on anthropometric measurements, for improving subjective clinical symptoms, and for promoting fertility outcome in obese patients with PCOS, who seek to become fertile. Methods: The study was conducted in the Tygerberg Hospital Infertility Clinic, as an experimental cohort. Patients with a body mass index (BMI) higher than 27, seeking fertility after diagnosis with PCOS, were referred for dietary consultation, and followed up 3 monthly over 1 year. At each visit anthropometric measurements and a detailed dietary history were taken and a questionnaire for clinical symptoms was completed.
Results: Baselinely, 86 patients were included in the study. Averages for weight and BMI were 99.8 ± 24.3 kg and 39.2 ± 8.7kg/m2, respectively. Average baseline daily fructose intake was 167 ± 116.8g. At baseline, significant relationships were shown between fructose intake and burning feet (ρ=0.02) and frequent waking (ρ=0.02), with a trend towards nightly eating (ρ=0.07). The dropout rate after visit 1 was 50%, with a further dropout of 41% after visit 2. After 3 visits (n=18), fructose intake significantly reduced (ρ=0.018), with the significant relationships with clinical symptoms having disappeared by visit 2. After 3 visits (n=18), both weight and BMI decreased significantly (ρ=0.017) and (ρ=0.019), respectively. Fructose was tested as a covariate to BMI, with high significance (ρ=0.006) in said population group.
Conclusion: Dietary intervention to reduce fructose intake proved significant for weight loss and BMI after 3 visits. Reduced fructose intake was associated with reduced clinical symptoms. With fructose being a significant covariate to BMI, it can be concluded that fructose overconsumption could possibly contribute to both clinical symptoms and elevated BMI in said study population.<br>AFRIKAANSE OPSOMMING: Die rol wat die beperking van fruktose speel bykomend tot dieetaanpassings en lewenstylverbetering vir gewigsverlies by oorgewig vroue met polisistiese ovariële sindroom (PCOS) in die uitkoms van fertiliteit en ander merkers van metaboliese sindroom.
Inleiding: Met die aanvang van hierdie studie was daar is geen data beskikbaar oor die invloed van die beperking van fruktose in die dieet van oorgewig pasiënte met PCOS wat vir gewigsverlies behandel word nie. Dit was ook nie bekend of laasgenoemde pasiënte se kliniese simptome en metaboliese/antropometriese profiel sou verbeter met die beperking van fruktose sodat fertiliteit by hierdie pasiënte terselfdertyd ook bevorder word nie. Doelwitte: Die evaluering van die aanvanklike inname van fruktose, sowel as die beperking van fruktose afkomstig van eetbare vrugte en versoete drankies en sap tot ’n inname van minder as 20 g daagliks, tesame met riglyne vir gewigsverlies. Die uitkoms hiervan is bepaal deur antropometriese metings, die verbetering in subjektiewe kliniese simptome en die fertiliteituitkoms by oorgewig pasiënte wat hulp met fertiliteit verlang.
Metodes: Die studie het as ’n eksperimentele kohort by die Infertiliteitskliniek by Tygerberg Hospitaal plaasgevind. Pasiënte wat na diagnose met PCOS fertiliteitsbehandeling verlang het en ’n BMI hoër as 27 gehad het , is vir dieetbehandeling verwys en driemaandeliks oor ’n tydperk van een jaar opgevolg. Tydens elke besoek is antropometriese metings en ’n omvattende dieetgeskiedenis geneem en ’n vraelys oor kliniese simptome ingevul. Resultate: Aanvanklik is 86 pasiënte by die studie ingesluit. Gemiddeldes vir gewig en BMI was 99.8 ± 24.3 kg en 39.2 ± 8.7 kg/m2 respektiewelik. Gemiddelde aanvanklike daaglikse inname van fruktose was 167 ± 116.8 g. Oorspronklik het betekenisvolle verhoudings tussen fruktose en die volgende bestaan: brandvoete (ρ=0.02) en veelvuldige episodes van nagtelike wakkerheid (ρ=0.02), met ’n neiging na nagtelike etery (ρ=0.07). Die uitvalsyfer na een besoek was 50% met ’n verdere uitvalsyfer van 41% na die tweede besoek. Na drie besoeke (n=18) het sowel die gewig as die BMI betekenisvolle afname getoon (ρ= 0.017) en (ρ=0.019), respektiewelik. Fruktose is as ’n belangrike kovariant vir BMI (ρ= 0.006) vir hierdie populasiegroep geïdentifiseer.
Gevolgtrekking: Dieetintervensie vir die vermindering van die inname van fruktose was beduidend vir gewigsverlies en afname in BMI na drie besoeke. Verminderde fruktose-inname het gelei tot die vermindering van kliniese simptome. Met fruktose as beduidende kovariant vir BMI kan die gevolgtrekking gemaak word dat die oor-inname van fruktose by hierdie studiepopulasie waarskynlik tot sowel kliniese simptome as BMI bygedra het.
Book chapters on the topic "Obese PCOS"
1
Shah, Duru, and Madhuri Patil. "Infertility Management in Lean Versus Obese PCOS." In ISGE Series. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63650-0_9.
Full text
2
Tatarchuk, Tatyana, Tetiana Tutchenko, and Olga Burka. "Special Considerations on Hyperandrogenism and Insulin Resistance in Nonobese Polycystic Ovaries Syndrome." In Androgens [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.103808.
Full textAbstract:
PCOS is a widespread phenotypically inhomogeneous endocrinopathy with significant health consequences and incompletely elucidated pathogenesis. Though visceral adiposity and insulin resistance (IR) is a well-proved pathogenic set of factors of PCOS, not all women with obesity and IR have PCOS and not all PCOS women are obese and have IR, which is explained by certain genetic backgrounds. The reported prevalence of nonobese PCOS (NonObPCOS) is about 20–30%, but it may be higher because especially in lean women with nonclassical phenotypes PCOS diagnosis is often delayed or unrecognized. Unlike obese PCOS, NonObPCOS management is less clear and is limited to symptomatic treatment. This chapter presents in structured fashion the existing results on the prevalence of NonObPCOS, as well as on special aspects of body composition, IR, and hyperandrogenism pathogenesis, including adrenal contribution in NonObPCOS.
3
Ingale, Kundan. "Polycystic Ovarian Syndrome in Lean and Obese Women." In Decoding Polycystic Ovarian Syndrome (PCOS). Jaypee Brothers Medical Publishers (P) Ltd., 2018. http://dx.doi.org/10.5005/jp/books/13089_11.
Full text
4
Ramanathan, Gunasekaran. "Effects of Acupuncture Treatment on Polycystic Ovary Syndrome (PCOS)." In Polycystic Ovary Syndrome - Symptoms, Causes and Treatment [Working Title]. IntechOpen, 2023. http://dx.doi.org/10.5772/intechopen.113799.
Full textAbstract:
Polycystic ovarian syndrome (PCOS) is an imbalance of endocrine hormones with a group of symptoms that occur in the reproductive age of females. It is diagnosed by androgen excess and ovarian dysfunction. Many pharmacological-based drugs and treatments are available, however, the effectiveness of existing therapies is less. Yet no cure for PCOS, but symptoms can be managed with medications and lifestyle modifications. Hence, an alternative treatment method is needed for a complete cure. Currently, much clinical evidence has revealed that Acupuncture (AP) and Electro-acupuncture treatment (EAT) are effective treatments for regulating reproductive hormone levels, normalizing testosterone, reducing ovarian cysts, enhancing ovulation, and weakening insulin resistance in normal and obese women with PCOS. Further, β-endorphin has a more crucial role in PCO, AP, or EAT, which may alter the formation of β-endorphin. The mechanism of AP and EAT for PCOS has not been widely reviewed so far. A good understanding of the AP and EAT would be helpful in women with PCOS. This chapter aimed to overview the probable mechanisms and experimental evidence-based data of acupuncture treatment on PCOS in animal models and human patients. We hope that the chapter study will contribute to a better understanding of the PCOS and AP treatment.
5
Panda, Subrat, Rituparna Das, Lisley Konar, and Manasi Singh. "Causes of Polycystic Ovarian Syndrome." In Polycystic Ovary Syndrome - Symptoms, Causes and Treatment [Working Title]. IntechOpen, 2024. http://dx.doi.org/10.5772/intechopen.113877.
Full textAbstract:
PCOS is a multifactorial syndromic disorder—the exact etiology is not known. Genetic, epigenetic, and environmental factors may be the causative factors. It is the most common cause of an-ovulatory infertility, and in adolescents, the young girl may present with irregular periods. Most of the women with PCOS are either overweight or obese. Another variety of PCOS women is lean. Sleep apnea, metabolic syndrome, and endometrial carcinoma are the late consequences of women with PCOS. As new research shows that gut microbiome is one of the attributing factors of PCOS, it will lead to a new horizon in the management of PCOS. Fecal implantation or probiotics may be helpful in PCOS management. Physical and emotional stress is one of the contributing factors to PCOS. Neuroendocrine factors are also an attributive factor for the development of PCOS. Most of the research about neuroendocrine factors is very preliminary and limited to the mice model. The incidence of PCOS varies from region to region as dietary and environmental factors differ. More human research is required to have more knowledge about the etiology of PCOS, which will guide the management of PCOS.
6
Sever, Mojca Jensterle, Simona Ferjan, and Andrej Janez. "Incretin System: New Pharmacological Target in Obese Women with Polycystic Ovary Syndrome." In Debatable Topics in PCOS Patients. InTech, 2018. http://dx.doi.org/10.5772/intechopen.70648.
Full text
7
Legro, Richard S. "Polycystic ovary syndrome: metabolic aspects." In Oxford Textbook of Endocrinology and Diabetes. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199235292.003.0857.
Full textAbstract:
Polycystic ovary syndrome (PCOS) is thought to be primarily a disorder that affects women during their reproductive years. The diagnostic criteria reflect ovarian dysfunction, i.e. hyperandrogenism, anovulation, and polycystic ovaries. However, women with PCOS appear to be uniquely insulin resistant, are frequently obese, and may be at risk for a variety of long-term health disorders including diabetes, cardiovascular disease, and cancers. Although the endocrine and reproductive features of the disorder improve with age, the associated metabolic abnormalities, particularly components of the metabolic syndrome, may actually worsen. This chapter will explore the pathophysiology of aberrant insulin action in women with PCOS, recognition of long-term risks, and preventive strategies.
8
Ehrmann, David A., and Susan Sam. "Polycystic Ovary Syndrome." In Oxford Textbook of Endocrinology and Diabetes 3e, edited by John A. H. Wass, Wiebke Arlt, and Robert K. Semple. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780198870197.003.0160.
Full textAbstract:
Insulin resistance is common among women with PCOS independent of adiposity. However, the severity of insulin resistance in these women worsens with obesity especially in those who present with the classical phenotype of PCOS (NIH criteria) consisting of hyperandrogenism and menstrual irregularity. Hence, obese women with PCOS, especially those with the classic phenotype of PCOS, are at high risk for metabolic complications. These complications include type 2 diabetes (DM2), metabolic syndrome, dyslipidaemia and obstructive sleep apnoea (OSA). Additionally, these women are at increased risk for cardiovascular disease even though the exact risk for this complication is not established. Due to heightened risk for metabolic disorders, close screening and follow-up for development of glucose intolerance, metabolic syndrome, and OSA is essential and is supported by current guidelines. Management of women with PCOS is individualized and should depend on the patient’s symptoms as well as their risk for development of various complications.
9
Leustean, Letitia, Simona Fica, Cristina Preda, et al. "Adiponectin in Obese PCOS Women — Size Does Matter." In The Endocrine Society's 93rd Annual Meeting & Expo, June 4–7, 2011 - Boston. The Endocrine Society, 2011. http://dx.doi.org/10.1210/endo-meetings.2011.part2.p32.p2-253.
Full text
10
Luz, Beatriz Coelho da, Paloma Esthefany Bezerra Martins, Amanda Alves Marcelino da Silva, Taisy Cinthia Ferro Cavalcante, Marília Tokiko Oliveira Tomiya, and Thays Kallyne Marinho de Souza. "Nutritional and clinical profile of women with polycystic ovary syndrome." In CONNECTING EXPERTISE MULTIDISCIPLINARY DEVELOPMENT FOR THE FUTURE. Seven Editora, 2023. http://dx.doi.org/10.56238/connexpemultidisdevolpfut-144.
Full textAbstract:
Polycystic ovary syndrome (PCOS) is a complex endocrine disease with heterogeneous clinical signs and symptoms, its main manifestations and clinical consequences being hyperandrogenism, and chronic anovulation, irregular menstrual cycles, presence of multiple cysts in the ovaries and decreased implantation potential embryonic. The aim of this study was to characterize the nutritional and clinical profile of women with Polycystic Ovary Syndrome. The study was carried out virtually using Google Forms from the Google platform, in which the link was made available on social networks. The form contained questions about sociodemographic information, symptoms related to PCOS, presence or absence of chronic noncommunicable diseases, anthropometric data and food consumption using a Food Frequency Questionnaire (FFQ). The participants were 41 women with a mean age of 23.83 ± 4.77 years, with a mean weight, height, BMI and waist circumference of 69.56 ± 17.21 Kg; 1.61 ± 0.06 m; 26.86 ± 7.13 kg/m²; 80.22 ± 12.62 cm; respectively. Most women had depression/anxiety (60.98%) and were overweight/obese (56.10%). The most reported PCOS symptom was menstrual dysfunction (90.24%). There was no statistical significance between the foods consumed and the symptomatology of PCOS (p>0.05). From this study, it is concluded that women with PCOS have a prevalence of overweight and depression and/or anxiety, also showing that the nutritional diagnosis based on the assessment of nutritional status and food consumption is of paramount importance to guide intervention strategies for treating PCOS such as changing lifestyle and eating habits.
Conference papers on the topic "Obese PCOS"
1
Strauss, Temima, Kiran Nandalike, Sanghun Sin, and Raanan Arens. "Upper Airway Structure And Body Fat Composition In Obese Adolescents With PCOS." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a3697.
Full text
2
Savadali, Seyfi, and Elmira Agayeva. "THE EFFECTS OF METFORMIN ON INSULIN RESISTANCE AND LEVELS OF SEKRETED KLOTHO AND LEPTIN IN OBESE WOMEN WITH PCOS." In XVII INTERNATIONAL INTERDISCIPLINARY CONGRESS NEUROSCIENCE FOR MEDICINE AND PSYCHOLOGY. LCC MAKS Press, 2021. http://dx.doi.org/10.29003/m2303.sudak.ns2021-17/326-327.
Full text